Clarinase 24 Hr Extended Release Adverse Reactions

During controlled clinical studies with the recommended dosage, the incidence of adverse effects associated with CLARINASE 24Hr Tablets was similar to that of placebo, with the exception of insomnia and dry mouth. Other reported adverse reactions associated with both CLARINASE 24Hr Tablets and placebo included headache and somnolence.
From post-marketing experience, isolated cases of acute generalized exanthematous pustulosis (AGEP), a form of severe skin reaction, have been reported with pseudoephedrine-containing products.
During the marketing of loratadine, the following adverse effects have been reported rarely: alopecia, anaphylaxis (including angioedema), abnormal hepatic function, dizziness, and convulsion.
There have been rare postmarketing reports of mechanical upper gastrointestinal tract obstruction in patients taking CLARINASE 24Hr Tablets. In most of these cases, patients have had a history of difficulty in swallowing tablets, or have had known upper gastrointestinal narrowing or abnormal esophageal peristalsis.